▸ Simple but novel design allowing tubing change without it being detached from the skin

▸ Appealingly shaped (optimal aesthetic usability and contour bias)

▸ Affords greater comfort and security for patients, encouraging mobilisation and promoting undisturbed sleep

▸ Reduces cannula loss and therefore contributes to timely IV fluid and drug administration

▸ Can be left on even after discharge home to fall off of its own accord, so reduces the risk of damaging delicate skin

▸ Holds and directs tubing away from the skin rather than forcing it against the skin

▸ Infection control guidelines easier to adhere to because administration tubing remains visible throughout its length

▸ No exposed adhesive surfaces

▸ Smooth curves prevent dust trapping

▸ Skin reactions can be continually monitored through the transparent base

▸ Economical manufacture from standard materials using a one-shot injection into a 2-part mould

▸ Fine tolerance injection moulding is critical for optimal function

▸ Clinical staff lack of familiarity with the device

▸ No obvious marketing opportunities as brand reminder or service to medicine

▸ Depends on each hospital deciding whether to allow staff access to it

▸ Clinical staff familiarity with adhesive tape

▸ Perception that tape is less expensive and ‘will do’

▸ Expensive skin-safe adhesive required from a third party specialist

▸ The size of the crystalloid administration market in the UK and rest of the developed world

▸ The possibility of making a range of products for tubing of different sizes

▸ Resistance to change

▸ Prior art and freedom to operate issues

▸ Stringent economic climate

▸ Demand for clinical trial data before cost saving can be claimed